In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Restructures for a More Flexible Future

Executive Summary

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
Advertisement

Related Content

Cliff Nearing, It's Lilly's Turn to Restructure
The GSK/Pfizer HIV Venture: Another Sign of Change?
Pfizer/Wyeth: Industrializing Pharma?
Pharma's New Marketing Realities
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
Pfizer's Increasingly Specialist Focus
PSA: What We Have Here Is A Failure to Innovate
Pfizer Deal Highlights Bristol's Biotech Swagger

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel